A Pralidoxime Nanocomplex Formulation Targeting Transferrin Receptors for Reactivation of Brain Acetylcholinesterase After Exposure of Mice to an Anticholinesterase Organophosphate.

"Disclosure E.H.C. and K.F.P. are two of the inventors of the described scL technology, for which several patents owned by Georgetown University have been issued. The patents have been licensed to SynerGene Therapeutics, Inc. for commercial development. K.F.P. serves as Principal Investigator for research at Georgetown University that is supported by SynerGene Therapeutics, Inc. E.H.C. owns an equity interest in SynerGene Therapeutics, Inc., and E.H.C. and A.R. serve as paid scientific consultants to SynerGene Therapeutics, Inc. S.S.K. is salaried employee of SynerGene Therapeutics, Inc. M.M. is a graduate student and M.G. an undergraduate student who were supported via a research agreement between Georgetown University and SynerGene Therapeutics, Inc. A.W. is a former paid employee of SynerGene Therapeutics, Inc. J.B.H. serves as salaried President & CEO of SynerGene Therapeutics, Inc. and owns stock in same. The authors report no other conflicts of interest in this work."

"The authors wish to thank Chris Poki Leung and Francis Cheung for their assistance with statistical analysis of the data presented here. The research described herein was supported in part by the Defense Threat Reduction Agency of the US Department of Defense through grant HDTRA1-13-1-0049 and contract HDTRA1-20-C-0045 to SynerGene Therapeutics, Inc. The content is solely the responsibility of the authors and does not necessarily reflect the official view of the Defense Threat Reduction Agency."